Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medivation Sees Potential For Combinations Out Of Opdivo Failure

Executive Summary

Failure of Bristol's PD-1 inhibitor Opdivo in first-line lung cancer may open doors for combination use with drugs with immune-activating properties, like prostate cancer drug Xtandi and PARP inhibitor talazoparib.

Advertisement

Related Content

Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Does CheckMate 026 Take Bristol Out Of The End Game?
Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors
AstraZeneca Sees Strength In Small Molecules, Starts Building Oncology Franchises

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register